Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,369,548
  • Shares Outstanding, K 16,883
  • Annual Sales, $ 277,130 K
  • Annual Income, $ 57,140 K
  • 60-Month Beta 1.10
  • Price/Sales 4.96
  • Price/Cash Flow 9.21
  • Price/Book 1.71
Trade LGND with:

Options Overview Details

View History
  • Implied Volatility 57.85% ( +9.88%)
  • Historical Volatility 35.54%
  • IV Percentile 78%
  • IV Rank 69.90%
  • IV High 65.14% on 06/17/22
  • IV Low 40.92% on 09/09/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 3,874
  • Open Int (30-Day) 3,903

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.15
  • Number of Estimates 1
  • High Estimate 0.15
  • Low Estimate 0.15
  • Prior Year 1.18
  • Growth Rate Est. (year over year) -87.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.50 +2.04%
on 09/23/22
104.79 -22.59%
on 08/25/22
-20.47 (-20.15%)
since 08/23/22
3-Month
79.50 +2.04%
on 09/23/22
109.00 -25.58%
on 08/15/22
-6.69 (-7.62%)
since 06/23/22
52-Week
72.57 +11.78%
on 06/14/22
169.98 -52.28%
on 11/10/21
-61.81 (-43.24%)
since 09/23/21

Most Recent Stories

More News
Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND : 81.12 (-0.47%)
AVEO : 7.75 (-4.67%)
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI ® (teclistamab)...

LGND : 81.12 (-0.47%)
AHPA : 10.19 (+0.30%)
Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates

Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LGND : 81.12 (-0.47%)
IDYA : 12.10 (+0.67%)
Ligand Reports Second Quarter 2022 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management...

LGND : 81.12 (-0.47%)
AHPA : 10.19 (+0.30%)
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 17.14% and 26.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 4.95 (-1.79%)
LGND : 81.12 (-0.47%)
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate...

LGND : 81.12 (-0.47%)
Ligand to Report Second Quarter Financial Results on August 8

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference...

LGND : 81.12 (-0.47%)
Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses

Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.

LGND : 81.12 (-0.47%)
ORA : 90.78 (-1.68%)
ZLNDY : 9.4550 (-3.81%)
RADI : 11.54 (-4.71%)
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jason Haas to the Company's Board of Directors. Mr. Haas brings more than 30 years...

LGND : 81.12 (-0.47%)
ASCO 2022: Surprising News in Cancer Research

The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.

ADPT : 6.50 (-5.80%)
LGND : 81.12 (-0.47%)
ACLX : 17.46 (-1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 84.01
2nd Resistance Point 82.78
1st Resistance Point 81.95
Last Price 81.12
1st Support Level 79.90
2nd Support Level 78.67
3rd Support Level 77.84

See More

52-Week High 169.98
Fibonacci 61.8% 132.77
Fibonacci 50% 121.27
Fibonacci 38.2% 109.78
Last Price 81.12
52-Week Low 72.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar